Rocket Pharmaceuticals Acquires Renovacor

Chardan Healthcare Acquisition 2 Corp. Completes Business Combination with Renovacor, Inc.

September 2, 2021

Biotechnology

Renovacor, an early‑stage biotechnology company developing AAV‑based gene therapies for BAG3‑associated cardiovascular and CNS diseases, closed a business combination with special purpose acquisition company Chardan Healthcare Acquisition 2 Corp. (CHAQ) and will begin trading on the New York Stock Exchange as Renovacor, Inc., with approximately $95.1 million of gross proceeds (including a $30.0 million PIPE) to fund clinical development into 2023. The transaction preserves Renovacor’s existing management team and provides public-market access and capital to advance its lead program, REN‑001, toward IND submission and a Phase I/II trial.

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences

March 25, 2024

Biotechnology

Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.

Rocket Companies Acquires Mr. Cooper Group

March 31, 2025

Financial Services

Rocket Companies (NYSE: RKT) announced a definitive all‑stock agreement to acquire Mr. Cooper Group Inc. and bring together Rocket's origination capabilities with Mr. Cooper's servicing platform to create an end‑to‑end homeownership platform. The deal was announced as an all‑stock transaction with $9.4 billion in equity value and later reported closed as a $14.2 billion acquisition; the combination is expected to drive significant recapture, data/AI synergies and roughly $500 million of annual run‑rate revenue and cost benefits.

Redwire Acquires Roccor

October 29, 2020

Aerospace & Defense

Redwire has acquired Roccor, a Longmont, Colorado manufacturer of deployable booms, structures, antennas, thermal products and solar arrays for small satellites. Terms were not disclosed; the deal adds Roccor’s flight‑proven hardware to the Redwire platform (a company formed and backed by private equity firm AE Industrial Partners) to expand Redwire’s space infrastructure capabilities.